Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07328529
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
Safety, Tolerability, and Efficacy of SRX246, a Vasopressin 1a Receptor Antagonist, in Aggressive Participants With Fragile X Syndrome
Sponsor: Azevan Pharmaceuticals
Conditions
Aggressive Behavior in Fragile X Syndome
Updated 1 time since 2026 Last updated: Jan 8, 2026 Started: Mar 31, 2026 Primary completion: Mar 31, 2027 Completion: Mar 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Aggressive Behavior in Fragile X Syndome and is currently actively recruiting participants. Azevan Pharmaceuticals leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Azevan Pharmaceuticals
- Congressionally Directed Medical Research Programs
Data source: Azevan Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .